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Background: In order to reduce the risk of recurrence, adjuvant treatment with an aromatase 
inhibitor (AI) is recommended for postmenopausal women following surgery for hormone 
receptor-positive breast cancer. AIs are associated with improved disease-free survival compared 
with tamoxifen. The adverse events associated with AIs resemble those of menopause, such as 
bone density loss and musculoskeletal symptoms.
Purpose: We examine the case of a postmenopausal woman who was prescribed anastrozole, a 
nonsteroidal AI, as adjuvant therapy following surgery for estrogen and progesterone receptor-
positive (ER and PgR+) breast cancer.
Methods and sample: A 58-year-old postmenopausal woman diagnosed with ER and PgR+ 
breast cancer was prescribed anastrozole as adjuvant therapy following a right-inferior quad-
rantectomy. After experiencing joint pain and stiffness, she was prescribed paracetamol and a 
topical nonsteroidal anti-inflammatory drug. She was also counseled on nonpharmacological 
interventions. However, she continued to experience symptoms, and reported that she was not 
taking anastrozole regularly.
Results: The case study patient ultimately found relief by switching to letrozole, another aro-
matase inhibitor. This approach is supported by recent studies examining the benefits of switching 
strategies between aromatase inhibitors in order to relieve symptoms of arthralgia/myalgia.
Conclusions: Both adherence and strategies for managing aromatase inhibitor-associated 
arthralgia are key to deriving maximal clinical benefit from AI therapy. Switching from one 
aromatase inhibitor to another may provide a viable option in managing adverse events and 
enhancing adherence to medication.
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Background
Guidelines such as the 2011 St Gallen International Consensus Statement, the 2010 
European Society for Medical Oncology (ESMO), and American Society of Clinical 
Oncology (ASCO) guidelines, and the 2011 National Comprehensive Cancer Network 
(NCCN) guidelines include recommendations that, following surgery for early hor-
mone receptor-positive (HR+) breast cancer, postmenopausal women receive adjuvant 
aromatase inhibitor (AI) treatment either as initial therapy or following 2–3 years of 
tamoxifen in order to reduce the risk of recurrence.1–4 The use of AIs as initial therapy, 
after 2–3 years of tamoxifen or after 5 years of tamoxifen, has been shown to be more 
effective than 5 years of adjuvant tamoxifen alone, resulting in an improvement in 
disease-free survival (DFS) and a reduction in breast cancer events.3,5 The ASCO 
recommendations take into account the fact that locoregional, distant recurrent, and 
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contralateral breast cancer have clinical consequences for 
breast cancer patients.3 The course of the disease is character-
ized by peaks in recurrence at 2 years and at 3.5 to 4 years 
following surgery for breast cancer; the majority of these 
recurrences are distant recurrences.6
In the Breast International Group (BIG) 1-98 trial, 
for example, upfront letrozole demonstrated a significant 
19% improvement in DFS (351 events with letrozole vs 
428 events with tamoxifen; P = 0.003), and a significant 
27% reduction in the risk of distant recurrence early on at 
25.8 months of follow-up (184 events with letrozole vs 249 
with t  amoxifen; P = 0.001).7 The early reduction in the risk 
of distant metastases with letrozole seemed to have had long-
term clinical implications on patient outcomes. At 76 months’ 
median follow-up in BIG 1-98, there was a significant 12% 
improvement in DFS (509 events vs 565 events; P = 0.03) and 
also a nonsignificant 13% improvement in overall survival 
(P = 0.08) with initial adjuvant letrozole compared with 
tamoxifen.8 Recently published data from the BIG 1-98 trial 
at 8 years’ follow-up demonstrated a significant advantage in 
overall survival with letrozole monotherapy over tamoxifen 
monotherapy.9
Although the recommended duration of adjuvant AI ther-
apy currently is 5 years according to the ESMO guidelines,2 
the NCCN guidelines note that the optimal duration of AI 
therapy is not known,4 and trials are currently investigating 
durations of up to 10 years.10–12 It is important to communicate 
with patients about how to prevent and manage the adverse 
events associated with AIs, which resemble the symptoms 
of menopause and include bone density loss, increased frac-
tures, arthralgia, and other musculoskeletal symptoms,3,13 and 
to reinforce the importance of staying on therapy to derive 
clinical benefits.
Case presentation
A 58-year-old postmenopausal woman had undergone natural 
menopause at 52 years old. She had no previous surgery prior 
to being diagnosed with breast cancer. Her body mass index 
(BMI) was 24.5 kg/m2 (height = 169 cm; weight = 70 kg). 
She did housework and considered herself active. She had 
a history of mild irritable bowel syndrome (IBS) triggered 
by certain foods and by stress. She had been taking calcium 
(1000 mg) and vitamin D (400 international units) as directed 
by her family physician, since the onset of menopause.
In 2007, a mass in her right breast was discovered by rou-
tine mammography. In 2007, the patient had a right inferior 
quadrantectomy with sentinel lymph node (SLN) biopsy for 
breast cancer, and a 1-cm tumor and two SLNs were resected. 
Pathology revealed that the tumor had tubular histology 
and was HER2 negative, and estrogen and progesterone 
receptor (ER and PgR) positive; both SLNs were negative 
for metastases. In July through September 2007, the patient 
underwent radiation therapy to the right breast. Scintigraphy 
for bone metastases, X-ray for lung and liver metastases, and 
ultrasound for liver metastasis were all performed, and each 
was negative. Her medical oncologist recommended 5 years 
of adjuvant endocrine therapy with an AI, and in July 2007, 
the patient initiated treatment with anastrozole 1 mg/day. 
A postoperative bone mineral density test showed borderline 
osteopenia (T-scores: lumbar spine −1.5; left femoral −0.9; 
right femoral −1.3), and the patient continued previous cal-
cium and vitamin D supplementation.
The patient was seen in the clinic for follow-up every 
3 months for the next 24 months. At the first visit, she had 
complaints of joint pain and stiffness, particularly in her wrists 
and knees, but she reported no effect on her normal activities. 
She did not want to take any medication for the stiffness, 
and she reported taking anastrozole 1 mg/day r  egularly. 
Paracetamol 1000 mg was prescribed on an as-needed basis 
with a follow-up phone call planned after 2 weeks.
At the follow-up phone call, the patient reported no 
relief with paracetamol, but she did not want to take addi-
tional medications. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) were suggested, but the patient had experienced 
problems in the past with this type of medication aggravat-
ing her intestinal symptoms. The problem of joint pain 
associated with AIs was reviewed with the patient, and 
nonpharmacological treatments such as stretching exercises, 
massage, and warm showers were suggested. The patient 
was not taking any homeopathic agents. The patient was still 
being seen every 3 months, and an evaluation was planned 
at 6 months.
At her 6-month visit, the patient reported being tired and 
achy, and she questioned how long AI therapy needed to 
continue. She reported taking anastrozole 1 mg/day regularly 
and paracetamol occasionally (1000 mg, 2–3 times per day), 
but was not doing any specific exercises, yoga, or physi-
cal therapy. The patient was prescribed a topical NSAID: 
diclofenac gel 1%, applied 2–3 times per day to affected 
areas. This led to some reduction in pain, and stiffness 
subsided, but the patient did not persist in using the topical 
formula as it was not effective in managing her pain.
At her 9-month visit, the patient was finding it difficult 
to keep up with her daily activities. She tried hot water 
baths at a nearby thermal spa, but did not persist with this 
intervention. The patient admitted that she had not been 
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taking anastrozole 1 mg/day regularly for the past month 
due to adverse event experiences. At this point, the option 
of a treatment change was discussed; it was decided that she 
would try a d  ifferent AI to see if it might be tolerated better, 
and letrozole 2.5 mg/day was then prescribed. The patient 
was to begin therapy 2 weeks after the visit, and have a clinic 
appointment after another 2 weeks.
The patient noticed an improvement in her joint symptoms 
after stopping anastrozole treatment. At the 2-week visit, she 
reported taking letrozole daily and was not experiencing joint 
stiffness. She received phone follow-ups at 2-week intervals, 
and at her clinic visit in July 2008, was no longer suffering 
from joint pain or stiffness. The patient is now 3 years past 
her initial breast cancer surgery and has been taking letrozole 
2.5 mg/day for more than 2 years.
Discussion
Adjuvant AI clinical trials: incidence  
of musculoskeletal symptoms
In clinical trials in postmenopausal women with HR+ breast 
cancer, both nonsteroidal (anastrozole and letrozole) and 
steroidal (exemestane) AIs have been associated with an 
increased incidence of arthralgia compared with tamoxifen 
or placebo. In the anastrozole (Arimidex; AstraZeneca, 
  Wilmington, DE), tamoxifen, alone or in combination (ATAC) 
trial of 5 years of initial adjuvant anastrozole compared 
with tamoxifen, the incidence of arthralgia at 68 months’ 
follow-up was significantly higher with anastrozole than 
with tamoxifen (35.6% vs 29.4%; P , 0.0001).14 It was 
noted that adverse events such as arthralgia were only 
recorded during the 5 years of active treatment and within 
the first 2 weeks after stopping treatment.15 Consequently, 
at 100 months of follow-up in ATAC, there was little differ-
ence in the incidence of arthralgia compared with previous 
reports,15 and the incidence of arthralgia was not reported 
at 120 months of follow-up.16 In the BIG 1-98 trial, at 
71 months of median follow-up, arthralgia was more com-
mon in women taking letrozole-containing regimens (letro-
zole monotherapy for 5 years, or the sequence of 2 years 
of letrozole or tamoxifen followed by 3 years of the other 
agent) than in women receiving tamoxifen monotherapy for 5 
years (31.9%–34.7% vs 30.1%; P = 0.05).8 In the tamoxifen 
exemestane adjuvant multinational (TEAM) trial, at 2.75 
years’ median follow-up, the incidence of arthralgia was 
17.9% with initial adjuvant exemestane and 9.2% with initial 
adjuvant tamoxifen (P # 0.001);17 at 5.1 years of median 
follow-up, the incidence of joint disorders was 36% with 
exemestane and 31% with sequential tamoxifen followed by 
exemestane (P , 0.0001).18 Similar results were seen in the 
Intergroup Exemestane Study (IES) trial, in which patients 
were  randomized after completing 2–3 years of tamoxifen.19 
At 55.7 months of median follow-up, significantly more 
patients who switched to exemestane reported arthralgia 
compared with patients who continued on tamoxifen for 
the rest of the 5-year treatment period (18.6% vs 11.8%; 
P , 0.0001).19 In an analysis at 91 months of median 
follow-up, including patients both on and post-treatment, the 
incidence of musculoskeletal pain was significantly higher 
with exemestane than with tamoxifen (37.6% vs 29.9%; 
P , 0.001).20 In the MA.17 trial of extended adjuvant letro-
zole compared with placebo in patients who had completed 
5 years of tamoxifen treatment, there was significantly more 
arthralgia at 30 months of median follow-up with letrozole 
than with placebo (25% vs 21%; P , 0.001).21
Adherence to adjuvant AI therapy
Suboptimal adherence to adjuvant medication regimen in 
postmenopausal women with HR+ breast cancer may lead to 
inappropriate therapeutic efficacy of prescribed medication 
(tamoxifen or an AI), and may also increase the risk of cancer 
recurrence and reduce disease survival rates. Recently published 
reviews indicate that nonadherence with tamoxifen and AI 
therapy is common, and adherence reported in clinical trials 
may differ significantly from that observed outside of the clinical 
trial setting.22,23 Studies of patients taking adjuvant endocrine 
therapy for HR+ breast cancer have shown nonadherence rates 
of 20%–50% at follow-up times ranging from 1–4.5 years 
following the start of endocrine therapy.24–27
Joint symptoms are frequently cited as reasons for 
discontinuing treatment.27–29 In a retrospective study of 
600 postmenopausal, HR+, early breast cancer patients 
receiving adjuvant AI therapy in a clinical practice setting 
(median follow-up 19.7 months), arthralgia and myalgia 
led to discontinuation of the AI in 45.5% and 17.8% of the 
101 patients who discontinued due to toxicity, respectively.28 
In another study, 20% of 56 breast cancer patients receiving 
AI therapy in a clinical practice setting discontinued due to 
new or worsening arthralgia or bone pain.29
Communicating with patients about AIs and present-
ing management strategies can help patients remain on 
t  reatment.27 The previously mentioned study of 56 patients 
in a clinical practice setting showed that discontinuation 
due to arthralgia or bone pain occurred within the first 
3 months of treatment, leading the authors to recommend 
monthly visits during the first 3 months of therapy in order 
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to address any issues and ensure that patients continue taking 
AIs.29 H  owever, monthly visits are generally not an option 
for patients in Europe and North America, and were not an 
option for the patient in our case.
It is also important to communicate with patients about 
the benefits associated with AIs and the risks of not taking 
their prescribed treatment.27 The use of adjuvant AIs has 
been associated with significant improvements in DFS in 
postmenopausal women with HR+ breast cancer (Table 1). A 
study using automated pharmacy records in a large integrated 
health system showed an increased risk of mortality at 10 
years in women with Stage I–III HR+ breast cancer who dis-
continued or were nonadherent to endocrine therapy; survival 
was significantly higher in patients who adhered to therapy 
compared with patients who were nonadherent (81.7% vs 
77.8%; P , 0.01).24 A study of breast cancer patients in 
a community setting showed that 1589 (35%) of the 4526 
patients receiving endocrine therapy had adherence rates 
that have been associated with an increased risk of mortality 
(adherence rates ,80%).30
Nurses can play a vital role in discussing adverse events 
with patients at each visit and also discerning whether they 
are taking their medications as prescribed. It has been sug-
gested that follow-up phone calls between visits may also 
be helpful in addressing any adverse events that may arise.27 
Other techniques to improve adherence include the use of aids 
such as calendars or pillboxes.27 Enlisting support from the 
patient’s family and friends is another important component 
to facilitating patient adherence.27
Managing musculoskeletal symptoms
Recommendations for the management of joint symptoms 
include pharmacological and nonpharmacological inter-
ventions, and also switching to a different AI. Breast cancer 
patients taking AIs have used NSAIDs such as ibuprofen 
as well as paracetamol for the relief of joint symptoms.29 
The patient in our case was prescribed paracetamol, which 
provided little relief. She did not want to take NSAIDs 
because of intestinal issues. However, it should be kept 
in mind that proton-pump inhibitors may be helpful in 
alleviating any gastrointestinal symptoms associated with 
NSAIDs.31 Use of a topical NSAID was associated with 
some relief of the patient’s pain, but not stiffness, and she 
did not continue using it.
As an alternative to painkillers, a number of different 
nutritional supplements are being investigated for the 
treatment of arthralgia associated with the use of AIs. 
A Phase II clinical study evaluating glucosamine plus 
chondroitin (estimated enrollment = 53) for the relief of 
joint pain and stiffness in postmenopausal breast cancer 
patients taking AIs is currently recruiting participants.32 In 
a report from this study that included 21 evaluable patients 
at 24 weeks, 80% of patients had experienced improvements 
in joint symptoms in their hands, knees, or both areas.33 
Supplementation with vitamin D to achieve a target 
concentration of 40 ng/mL 25-hydroxyvitamin D has also 
been associated with a decreased risk of new and worsening 
arthralgia in a prospective cohort study of postmenopausal 
breast cancer patients initiating AI therapy.34 Additional 
studies (one recently completed Phase I/II study and two 
Phase II studies currently in progress) have been investigating 
the use of vitamin D for arthralgia in postmenopausal women 
with breast cancer who are taking AIs.35–37
Nonpharmacological treatments for arthralgia associated 
with AIs include lifestyle changes such as exercise and weight 
loss; these may be more appropriate for patients with mild 
symptoms.31 Interestingly, compared with postmenopausal 
breast cancer patients with BMI , 25 kg/m2, the prevalence 
Table 1 DFS benefits in selected trials of adjuvant AI therapy in postmenopausal women with HR+ breast cancer7,8,14,16–21,45
Clinical trial Follow-up Treatment arms Adjuvant setting DFS
ATAC 68 months Anastrozole vs tamoxifen Initial HR = 0.83; P = 0.005a
ATAC 100 months Anastrozole vs tamoxifen Initial HR = 0.85; P = 0.003a
ATAC 120 months Anastrozole vs tamoxifen Initial HR = 0.86; P = 0.003a
BIG 1-98 25.8 months Letrozole vs tamoxifen Initial HR = 0.81; P = 0.003
BIG 1-98 76 months Letrozole vs tamoxifen Initial HR = 0.88; P = 0.03
TEAM 2.75 years Exemestane vs tamoxifen Initial HR = 0.89; P = 0.12
TEAM 5.1 years Exemestane vs tamoxifen→exemestane Sequential HR = 0.97; P = 0.60b
IES 55.7 months Exemestane vs tamoxifen Switch HR = 0.76; P = 0.0001
IES 91 months Exemestane vs tamoxifen Switch HR = 0.84; P = 0.002
MA.17 30 months Letrozole vs placebo Extended HR = 0.58; P , 0.001
Notes: aResults for HR+ subpopulation; b5-year DFS.
Abbreviations: AI, aromatase inhibitor; ATAC, anastrozole (Arimidex), tamoxifen, alone or in combination; BIG, Breast International Group; DFS, disease-free survival; 
HR+, hormone receptor-positive; IES, Intergroup Exemestane Study; TEAM, tamoxifen exemestane adjuvant multinational.
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of joint pain appears to be reduced in postmenopausal breast 
cancer patients who are overweight (BMI 25–30 kg/m2) but not 
in those who are obese (BMI . 30 kg/m2).38 This observation 
may be attributed to increased adipose tissue in overweight 
women, resulting in increased levels of estrogen and other sex 
hormones, since joint problems in women taking AIs or in nor-
mal menopause appear to be related to a reduction in estrogen 
levels.38 However, obesity is associated with an increased risk 
of osteoarthritis; this may negate the protection from arthralgia 
afforded by the increased levels of estrogen.38
Warm showers, physical therapy, massage, and acupunc-
ture may also provide relief of arthralgia symptoms.39,40 In a 
randomized, blinded, sham-controlled study in 51 postmeno-
pausal patients with early breast cancer and self-reported 
musculoskeletal pain while taking AIs, acupuncture was 
effective in reducing joint pain and stiffness and improving 
functional ability and physical wellbeing.40 Several of these 
interventions were presented to our patient, but she was not 
amenable to physical therapy or exercises, and did not persist 
in going to a thermal spa for the temporary relief she received 
from hot water baths.
Switching from one nonsteroidal AI to another is another 
strategy that may allow patients experiencing arthralgia on 
one AI to continue adjuvant AI therapy. This is the treatment 
strategy that ultimately allowed our patient to find relief for 
her symptoms and to continue the benefits of adjuvant AI 
therapy. In the Anastrozole versus Letrozole: Investigation 
into Quality of Life and Tolerability (ALIQUOT) study of 
adjuvant AIs in postmenopausal women with HR+ breast 
cancer, the incidence of joint pain was similar with letrozole 
and with anastrozole (40%–49% vs 52%).41 However, 
approximately half of the patients in ALIQUOT with joint 
symptoms on letrozole did not report joint symptoms on 
anastrozole, and vice versa (Table 2).42 In the Articular 
Tolerance of Letrozole (ATOLL) study and a study by Yardley 
et al, a majority of postmenopausal women with HR+ breast 
cancer who discontinued anastrozole due to musculoskeletal 
symptoms were able to continue therapy with letrozole for 
at least 6 months: 71.5% in ATOLL and 87.4% in Yardley 
et al (Table 2).43,44
Conclusions
Approaches to alleviate musculoskeletal symptoms in 
postmenopausal breast cancer patients taking AIs include 
pharmacological interventions (such as NSAIDs or vitamin 
D supplementation), nonpharmacological interventions (such 
as homeopathy or lifestyle changes including exercise and 
weight loss), and switching between nonsteroidal AIs. While 
offering greater clinical efficacy than tamoxifen, switching 
from one AI to another can provide relief of joint pain and 
stiffness for some postmenopausal women taking adjuvant 
AIs for HR+ breast cancer. It is important to address the 
adverse events associated with AIs and also to provide strat-
egies for managing them so that in order to derive the most 
clinical benefit, patients remain adherent to therapy.
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Table 2 Studies of switching from one AI to another in postmenopausal women with HR+ breast cancer to address musculoskeletal 
symptoms
Study N Study design Results Reference
ALIQUOT 182 Open-label, crossover study 
12 weeks of letrozole followed by 12 weeks of anastrozole,  
or 12 weeks of anastrozole followed by 12 weeks of letrozole
56% had joint problems on letrozole  
but not on anastrozole 
55% had joint problems on anastrozole  
but not on letrozole
41,42
ATOLL 179 Prospective, nonrandomized, open-label, multicenter study 
Patients who discontinued anastrozole due to musculoskeletal  
symptoms initiated letrozole for 6 months or until  
discontinuation due to intolerance or disease progression
71.5% of patients on letrozole at  
6 months 
28.5% discontinued due to  
musculoskeletal symptoms
43
Yardley et al44 261 Patients who discontinued anastrozole due to grade 2 or 3  
arthralgia/myalgia initiated letrozole for 6 months
87.4% of patients on letrozole at  
6 months 
9.6% discontinued due to arthralgia/ 
myalgia
44
Abbreviations: AI, aromatase inhibitor; ALIQUOT, Anastrozole versus Letrozole: Investigation into Quality of Life and Tolerability; ATOLL, Articular Tolerance of Letrozole; 
HR+, hormone receptor-positive.
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